Ravulizumab (Anti-Complement C5)
Synonyms: ALXN1210
Ravulizumab (Anti-Complement C5) is a humanised monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, and myasthenia gravis. MW: 145.5 KD.
Quality Control
Mechanism of Action
| Description |
Ravulizumab (Anti-Complement C5) is a humanised monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, and myasthenia gravis. MW: 145.5 KD.
|
|---|
Product Details
| CAS No. | 1803171-55-2 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG2SA |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
Comparison of Clones for
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tech Support
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.